Uniunea Europeană - română - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - imunosupresoare - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

abbvie s.r.l. - italia - risankizumabum - sol. inj. in seringa preumpluta - 150mg/1ml - imunosupresoare inhibitori de interleukina

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

abbvie s.r.l. - italia - risankizumabum - sol. inj. in stilou injector preumplut - 150mg/1ml - imunosupresoare inhibitori de interleukina

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

abbvie deutschland gmbh & co. kg - germania - risankizumabum - sol inj. in cartus - 150 mg/ml - imunosupresoare inhibitori de interleukina

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

abbvie s.r.l. - italia - risankizumabum - conc. pt. sol. perf. - 60 mg/ml - imunosupresoare inhibitori de interleukina

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

abbvie s.r.l. - italia - risankizumabum - sol. inj. in seringa preumpluta - 75mg/0,83ml - imunosupresoare inhibitori de interleukina